← Human Trials & Peer-Reviewed Studies
Human choriogonadotropin and epoetin alfa in acute ischemic stroke patients (REGENESIS-LED trial)
Plain-language guide to PMID 24588854 (2014): double-blind randomized controlled trial study of hCG (human chorionic gonadotropin).
Key Facts
- PMID
- 24588854
- Journal
- International journal of stroke : official journal of the International Stroke Society
- Year
- 2014
- Study type
- Randomized Controlled Trial
- Authors
- Cramer SC et al. (2 authors)
- DOI
- 10.1111/ijs.12260
What This Study Did, in Plain Language
What Was Tested
Researchers studied hCG (human chorionic gonadotropin) in this randomized controlled trial publication.
A proof of concept trial (REGENESIS) was initiated but placed on regulatory hold during review of an erythropoietin neuroprotective trial.
Who Took Part
By PubMed's age tags, the people studied were teenagers, young adults, adults, middle-aged adults, older adults and people over 80, both men and women.
Entry criteria included National Institutes of Health Stroke Scale 8-20, supratentorial ischemic stroke, and 24-48 h poststroke at start of therapy.
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
Because people in this hCG (human chorionic gonadotropin) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Blinding on both sides kept the participants and researchers unaware of who received hCG (human chorionic gonadotropin).
A placebo (an inactive look-alike) gave the hCG (human chorionic gonadotropin) group a baseline to be compared against.
Primary outcomes were safety and neurological recovery.
What Was Measured
PubMed files the paper under topics including Brain Ischemia, Chorionic Gonadotropin, Cohort Studies, Epoetin Alfa, Erythropoietin, Hematinics and International Cooperation.
Author keywords: clinical trial, growth factor, restorative, safety and stroke recovery.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of hCG (human chorionic gonadotropin).
Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2014 (International journal of stroke : official journal of the International Stroke Society), a journal based in United States.
More context: the hCG (human chorionic gonadotropin) compound page, all human trials.
Our Notes on the Compound
hCG (human chorionic gonadotropin): An LH analog that drives Leydig-cell testosterone production.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.